Scientists at deCODE genetics, a subsidiary of AMGEN, have discovered rare sequence variants, predicted to cause a loss of function of ITSN1, that are associated with a high risk of Parkinson’s disease. The findings also support less studied pathways involved in the pathogenesis of the disease.
The study, published in npj Parkinson’s Disease, used whole-genome sequence data from Iceland (deCODE genetics), the UK (UK Biobank), and the US (Accelerating Medicines Partnership Parkinson’s disease).
The role of ITSN1, Intersectin-1, is to activate CDC42, a small Rho GTPase involved in the growth and maintenance of dopaminergic neurons and the regulation of vesicle exocytosis of α-synuclein, whose accumulation is a pathological hallmark of Parkinson’s disease.
The researchers propose that loss of ITSN1 function may contribute to Parkinson’s disease pathogenesis through inactive CDC42 and its downstream pathways, degeneration of dopaminergic neurons and dysregulated vesicle exocytosis of α-synuclein, and/or through disrupted synaptic vesicle transport via clathrin-mediated endo- and exocytosis.
This suggests that targeting CDC42 or its upstream regulator, ITSN1, might offer a therapeutic approach for Parkinson’s disease.
More information:
Loss-of-function variants in ITSN1 confer high risk of Parkinson’s Disease., npj Parkinson’s Disease (2024). DOI: 10.1038/s41531-024-00752-9.
Provided by
deCODE genetics
Citation:
Researchers discover rare sequence variants that associate with a high risk of Parkinson’s disease (2024, August 15)
retrieved 15 August 2024
from https://medicalxpress.com/news/2024-08-rare-sequence-variants-associate-high.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
